David Coussens, MD
Urology · Little Rock, ARNPI 1538134283
Payments from drug & device makers
Across 394 payments — averaging $340.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cryo Specialty Medical, LLC$125K
- Angiodynamics, Inc.$3K
- Astellas Pharma US Inc$824
- Boston Scientific$529
- AbbVie$515
- Rochester Medical Corporation$458
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$13,50010%
- Travel & lodging$1,6551%
- Food & beverage$7,7746%
- Education$1900%
- Ownership interest$111,00083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cryo Specialty Medical, LLC | 11 | $124,500 |
| Angiodynamics, Inc. | 7 | $2,510 |
| Astellas Pharma US Inc | 46 | $824 |
| Boston Scientific | 46 | $529 |
| AbbVie(2 entities) | 32 | $515 |
| Rochester Medical Corporation | 29 | $458 |
| Coloplast | 19 | $439 |
| Sumitomo Pharma America, Inc. | 20 | $399 |
| Dendreon Pharmaceuticals LLC | 19 | $388 |
| Novartis | 19 | $374 |
| Pfizer | 21 | $364 |
| Johnson & Johnson | 14 | $309 |
| Cipla USA Inc. | 1 | $246 |
| Myriad Genetic Laboratories, Inc. | 13 | $243 |
| Myovant Sciences Inc. | 15 | $235 |
| Verity Pharmaceuticals Inc. | 12 | $235 |
| Amgen | 10 | $152 |
| Terumo Medical Corporation | 1 | $140 |
| Bayer | 8 | $134 |
| Endo Pharmaceuticals Inc. | 2 | $125 |
| Accord Healthcare, Inc. | 7 | $121 |
| Blue Earth Diagnostics | 7 | $117 |
| Axonics, Inc. | 2 | $116 |
| Teleflex LLC | 6 | $101 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $84 |
| Tolmar, Inc. | 3 | $78 |
| Merck | 3 | $56 |
| Antares Pharma, Inc. | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 2 | $49 |
| Palette Life Sciences, Inc. | 3 | $47 |
| Foundation Medicine, Inc. | 1 | $45 |
| Civco Medical Instruments | 2 | $29 |
| Medtronic | 2 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Cure Medical LLC | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Neotract Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$2,482
- ANGIO-SEAL$140
- Azur CX Detachable$140
- XIAFLEX$113
How this compares
$134,119 in reported general payments places this provider in the 90th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 54 | $36,225 |
| MyrbetriqMirabegron | 38 | $19,035 |
| Tamsulosin Hcl | 841 | $13,381 |
| Trospium Chloride | 132 | $7,098 |
| Silodosin | 60 | $5,865 |
| Finasteride | 346 | $3,899 |
| Methenamine Hippurate | 62 | $3,033 |
| Estradiol | 41 | $2,677 |
| Dutasteride | 106 | $2,544 |
| Solifenacin Succinate | 72 | $2,120 |
| NitrofurantoinNitrofurantoin Macrocrystal | 46 | $2,081 |
| Cephalexin | 146 | $1,161 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 66 | $1,134 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 69 | $1,127 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 47 | $799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $399 | $36,22554 claims |
| Astellas Pharma US IncMyrbetriq | $824 | $19,03538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Richard D AnnaLittle Rock$737K
- Donald MooneyLittle Rock$562K
- Timothy LangfordLittle Rock$180K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- Kevin ClaybrookLittle Rock$132K
- John MooreLittle Rock$128K
- Gail JonesLittle Rock$128K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.